ºããå^?(TMF)ÊÇÌæŵ¸£Î¤µÄÒ»ÖÖÐÂÐÍÇ°µÏÍþ¹ú¼Ê£¬ÔÚÖйú´ó½¹ã·ºÓÃÓÚÖÎÁÆÂýÐÔÒÒÐ͸ÎÑ×£¨CHB£©¡£ÏÈÇ°µÄ¢óÆÚ×¢²áÑо¿£¨NCT03903796£©ÒѾ­È·¶¨ÁËTMFÔÚ¿¹²¡¶¾ÁÆЧÉÏ·ÇÁÓÓÚ¸»ÂíËáÌæŵ¸£Î¤¶þßÁß»õ¥£¨TDF£©£¬Í¬Ê±ÏÔʾ³ö¸ü¸ßµÄ±û°±Ëáת°±Ã¸£¨ALT£©¸´³£Âʺ͸ÄÉƵĹÇ÷ÀºÍÉöÔలȫÐÔ¡£ÕâÏî¢ôÆÚÑо¿½øÒ»²½Õ¹Ê¾ÁËTMFµÄ³¤ÆÚÁÆЧºÍ°²È«ÐÔ¡£

¡¾Ñо¿·½·¨¡¿

Íê³ÉTMF¢óÆÚ×¢²áÊÔÑéµÄÊÜÊÔÕßÈë×é¸Ã¢ôÆÚÑо¿£¬ËùÓÐÊÜÊÔÕß¼ÌÐøÿÌì¿Ú·þTMF25mg¡£±¾´ÎÖÐÆÚ·ÖÎöµÄÖ÷ÒªÁÆЧÖÕµãÊǵÚ5ÄêѪÇåHBV DNAˮƽµÍÓÚÖÐÐÄʵÑéÊÒ¼ì²âÏÂÏ޵IJÎÓëÕß±ÈÀý¡£

¡¾Ñо¿½á¹û¡¿

×ܹ²ÓÐ639Àý£¨63.8%£©²ÎÓëÕßÈë×飬 589Àý»¼ÕßÄÉÈë·ûºÏ·½°¸¼¯£¨PPS£©·ÖÎö£¬ÆäÖаüº¬TMFÖÎÁÆ×é399Àý£¬TDFת»»TMF×飨TDF-TMF£©190Àý£¬Á½×éµÄ»¼ÕßÌØÕ÷ÔÚ»ùÏßÉÏ£¨µÚ3Ä꣩·Ö²¼¾ùºâ¡£ÖÁµÚ5Ä꣬TMF×éºÍTDF-TMF×é´ïµ½HBV DNA <20 IU/mLµÄ±ÈÀý·Ö±ðΪ95.2%ºÍ94.1%£¬±ÈµÚ3Äêʱ·Ö±ðÌá¸ßÁË5.5%ºÍ7.3%¡£Á½×éÖзֱðÓÐ91.9%ºÍ91.5%µÄ»¼Õß´ïµ½HBV DNA <10 IU/mL¡£Õû¸öÑо¿Æڼ䣬HBeAgתÒõÂʲ»¶ÏÔö¼Ó£¬µÚ5ÄêʱTMF×éºÍTDF-TMF×éµÄHBeAgתÒõÂÊ·Ö±ð´ïµ½68.0%ºÍ63.4%¡£Í¬Ê±£¬µÚ5ÄêTMF×éÀÛ¼ÆÓÐ24.8%µÄ»¼ÕßʵÏÖHBeAgѪÇåѧת»»¡£5ÄêÆÚ¼äÁ½×鹦ÄÜÐÔÖÎÓú£¨HBsAg<3000 IU/mL£©ÓÅÊÆÈËȺ±ÈÀý¾ù²»¶ÏÉý¸ß£¬ÖÁµÚ5Ä꣬×ÜÌåÈËȺÖй¦ÄÜÐÔÖÎÓúÓÅÊÆÈËȺռ±È´ï63%¡£TMF³ÖÐøÖÎÁÆ5ÄêÆÚ¼äµÄÀÛ»ý²¡¶¾Ñ§Ä͵ÏÍþ¹ú¼ÊÂÊΪ0¡£ÔÚALT¸´³£·½Ã棬TMFÖÎÁÆʹµÃTDF-TMF×黼ÕßµÄALT¸´³£ÂÊÔÚµÚ5Äê¼ÌÐøÉý¸ß£¬»ùÓÚAASLD±ê×¼Ïà±ÈµÚ3ÄêÌá¸ßÁË4.6%¡£¾­¹ýTMFµÄת»»ÖÎÁÆ£¬TDF¶Ô»¼ÕߵĸÎËðÉ˵õ½ÁËÄæת£¬ÖÁµÚ5Äêʱ£¬Á½×éµÄALT¸´³£ÂÊÒÑÎÞÏÔÖøÐÔ²îÒì¡£°²È«ÐÔ·½Ã棬µÚ3ÄêÖÁµÚ5ÄêÖÎÁÆÆÚ¼ä×ÜÌ尲ȫÐÔÁ¼ºÃ£¬ÑÏÖز»Á¼Ê¼þ£¨SAE£©·¢ÉúÂʵͣ¨2.7%£©¡£ÖÁµÚ5Äêʱ£¬53.9%µÄ»¼ÕßÑü×µ¹ÇÃܶÈZÖµÆÀ·ÖÏÔʾÔö¼Ó£¬TMF×éºÍTDF-TMF×éÖ®¼äÎÞÃ÷ÏÔ²îÒì¡£ÔÚ×ÜÌåÈËȺÖУ¬¹ÀËãÉöСÇòÂ˹ýÂÊ£¨eGFR£©<60 ml/min/1.73 m2µÄÀÛ»ý·¢ÉúÂÊÔÚ5ÄêÆÚ¼äһֱά³ÖÔڽϵÍˮƽ£¨0.0%~0.5%£©£¬×ܵ¨¹Ì´¼/¸ßÃܶÈÖ¬µ°°×µ¨¹Ì´¼£¨TC/HDL£©±ÈÖµÒ²±£³ÖÎȶ¨£¬ÌåÖؽöÓÐÇá΢Ôö¼Ó¡£

¡¾Ñо¿½áÂÛ¡¿

ºããå^?ÖÎÁÆÂýÐÔÒÒÐ͸ÎÑ×»¼Õß5ÄêÁÆЧºÍ°²È«ÐÔÁ¼ºÃ¡£ÎÞÂÛÊÇTMF³ÖÐøÖÎÁÆ×黹ÊÇTDFת»»TMFÖÎÁÆ×飬ÔÚ½ÓÊÜTMF¼ÌÐøÖÎÁƺó¾ùά³Ö¸ß²¡¶¾Ñ§Ó¦´ðÂÊ£¬ÉõÖÁʹ¾ø´ó²¿·Ö£¨>90%£©»¼ÕßʵÏÖÁËHBV DNA<10 IU/mL¡£³¤ÆÚTMFÖÎÁÆ»¹³ÖÐøÌá¸ßÁËHBeAgתÒõºÍѪÇåѧת»»µÄ»¼Õß±ÈÀý¡£´ËÍ⣬¹Ç¡¢ÉöºÍÖ¬ÖÊ°²È«ÐÔ²ÎÊýÔÚÑо¿ÆÚ¼äά³ÖÎȶ¨¡£¸ÃÑо¿ÈÔÔÚ½øÐÐÖУ¬Î´À´»¹½«ÓнøÒ»²½µÄËæ·Ã½á¹û¡£

[1]Jinlin Hou,et al.5-Year Efficacy and Safety of Tenofovir Amibufenamide in Chronic Hepatitis B Patients.APASL 2025.OP0155

[2]Jia Liu,et al.Evaluation of Antiviral and Immunomodulatory Effects of Tenofovir amibufenamide in Chronic HBV-replication Mouse Models. APASL 2025.OP0312

[3]Zhihong Liu,et al. New generation nucleotide analogues in treating chronic hepatitis B within Asian population: a systematic review and network meta analysis of randomized controlled trials. APASL 2025.EP0154

[4]Ruyue Chen,et al. Safety and Effectiveness of Tenofovir Amibufenamide for Pregnant Women with Chronic Hepatitis B. APASL 2025.PP0187

[5]Yuehang Wang,et al. Effectiveness and Safety of 48-Week Tenofovir Amibufenamide in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma: A Retrospective Real-World Study. APASL 2025.PP0245

[6]Jing Cui,et al. Analysis of the Short-term Efficacy and Safety of Tenofovir Amibufenamide in the Treatment of Patients with HBV-related Acute-on-chronic Liver Failure. APASL 2025.PP0853

[7]Xiao Chuan Diao,et al.Comparative efficacy and safety of tenofovir amibufenamide vs tenofovir alafenamide and entecavir in the hepatitis B virus related acute-on-chronic liver failure patients: A single-centre retrospective study. APASL 2025.PP0192

[8]Jie Li,et al. Evaluation of the therapeutic efficacy of alafenamide fumarate and tenofovir amibufenamide in the treatment of chronic hepatitis B patients with concomitant hyperlipidemia. APASL 2025.EP0120

[9]JUN LI,et al.A real-world study of the efficacy of tenofovir amibufenamide (TMF) in the treatment of patients with chronic hepatitis B and its effect on blood glucose and lipid levels. APASL 2025.PP0189

[10]Jishen Zhang,et al. The effect of tenofovir amibufenamide on lipid metabolism in patients with chronic hepatitis B is less than that of tenofovir alafenamide. APASL 2025.PP0196